Assess whether AI is delivering measurable value in biotech. Evidence from drug discovery, clinical trials, investment trends, and how to spot substantive AI companies.
AI in Biotech: Real Growth or Hype? A Practical Read for Investors and Researchers Read More »
How the UK’s NHS and national commission recommendations inform safe, proportionate AI regulation in healthcare and practical steps for adoption.
AI Governance in Healthcare: Lessons from the UK’s NHS Push Read More »
First clinical negligence claims over AI in the NHS force a rethink of who bears diagnostic risk. What this means for trusts, clinicians, developers and procurement.
NHS Faces Landmark AI Negligence Claims: Redefining Health Tech Liability Read More »
The UK’s independent commission proposes ‘L-plates’ staged approvals and continuous monitoring for AI medical devices, balancing faster access with patient safety.
Tamara Everington, Chief Medical Officer at Queen Victoria Hospital NHS Foundation Trust
By Kevin Monk, CEO and Co-founder at SARD JV
AI with intent and how Marion is changing how we think about work at SARD Read More »
MHRA sets out recommendations for regulating medical AI in the UK, addressing dynamic models, patient consent, bias and global cooperation to protect safety and trust.
UK Moves to Regulate AI in Healthcare: MHRA Issues Blueprint for Safe Use Read More »
72% of US pharma firms are scaling AI in R&D, yet only 24% expect large gains in drug success. A concise look at adoption, limits, and the human factor.
US Pharma’s AI Paradox: Widespread Adoption, Measured Expectations in Drug Discovery Read More »
A concise look at where AI is driving change in healthcare today: diagnostics, personalized care, operations, and the ethical guardrails shaping the future.
How AI Is Reshaping Healthcare: Diagnostics, Operations, and Ethics Read More »
North Rhine-Westphalia is investing €200M in AI4CancerCure.NRW to unite university hospitals and TU Dortmund, advancing AI-driven drug design, diagnostics and precision oncology.
